Literature DB >> 1693645

Interleukin-2 and the IL-2 receptor: new insights into structure and function.

W A Kuziel1, W C Greene.   

Abstract

Interleukin-2 (IL-2) was originally identified in 1976 as a growth factor for T lymphocytes. Since that time it has become an important mediator of immune function through its effects on the growth, development, and activity of T and B lymphocytes, natural killer cells, and lymphokine-activated killer cells. Only cells that bear a specific receptor for IL-2 respond to its immunoregulatory effects. Of all the lymphokine-receptor systems in immunology, perhaps most is known about the structure, function, and binding properties of IL-2 and its cognate receptor. There are two distinct, membrane-associated IL-2 binding components in the high-affinity IL-2 receptor: an alpha subunit and a beta subunit, which associate in a non-covalent manner. Each of these polypeptides can occur on the cell surface in the absence of the other and bind IL-2, although with only low or intermediate affinity relative to the high-affinity receptor complex. The primary structure of each chain has now been deduced from full-length cDNA. The rapid rate of association between IL-2 and the IL-2R alpha subunit is important in the formation of high-affinity binding sites, and the inducibility of the alpha gene contributes to the highly regulated and transient display of high-affinity IL-2R. The IL-2R beta chain controls the slow dissociation rate of IL-2 from the high-affinity receptor. Also, IL-2R beta appears centrally involved in internalization of IL-2 and signal transduction, functions mediated presumably through its long intracytoplasmic domain. However, the actual mechanism of signal transduction in the IL-2/IL-2R system remains undefined. IL-2R beta is a member of a novel family of cytokine-receptor proteins that includes receptors for IL-4, IL-6, and erythropoietin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693645     DOI: 10.1111/1523-1747.ep12875017

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  CD25 preselective anti-HIV vectors for improved HIV gene therapy.

Authors:  Stefanos Kalomoiris; Je'tai Lawson; Rachel X Chen; Gerhard Bauer; Jan A Nolta; Joseph S Anderson
Journal:  Hum Gene Ther Methods       Date:  2013-01-11       Impact factor: 2.396

3.  Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

Authors:  G H Bock; J R Ongkingco; L T Patterson; J Ruley; L R Schroepfer; D L Nelson
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

Review 4.  Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?

Authors:  M J Weldon; J D Maxwell
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

5.  The interleukin-2 receptor in lesions and serum of bullous pemphigoid.

Authors:  D Zillikens; A Ambach; M Schuessler; R Dummer; A A Hartmann; G Burg
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

6.  In vitro Production of IL-6 and IFN-γ is Influenced by Dietary Variables and Predicts Upper Respiratory Tract Infection Incidence and Severity Respectively in Young Adults.

Authors:  Huicui Meng; Yujin Lee; Zhaoyong Ba; Jennifer A Fleming; Emily J Furumoto; Robert F Roberts; Penny M Kris-Etherton; Connie J Rogers
Journal:  Front Immunol       Date:  2015-03-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.